Brief: Orexo Q2 EBITDA Loss Widens To SEK 41.1 Mln
July 15 (Reuters) - Orexo AB ORX.ST :
* OREXO Q2 2021 INTERIM REPORT
* Q2 TOTAL NET REVENUES OF SEK 142.8 M (179.1)
* Q2 EBITDA OF SEK -41.1 M (-9.0)
* Q2 NET EARNINGS OF SEK -73.7 M (-32.5)
* Q2 OF 2021 SHOWED SOME POSITIVE OPERATIONAL HIGHLIGHTS IN
BOTH
OUR DIGITAL THERAPEUTICS (DTX) BUSINESS AND US PHARMA
Source text for Eikon: ID:nWkr9kwbhg
Further company coverage: ORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens